GlassScriptPhysician profile
Nicole A Lieber
NPI 1023532371
$1,276.02
in general payments reported to CMS, 2019-2025
23 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.73 · 2023: $409 · 2024: $439 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,230.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $148.46 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $124.48 | 2022-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $124.40 | 2022-2023 | Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $115.58 | 2023-2025 | |
| Emd Serono, INC. | $86.93 | 2023-2024 | Tepmetko |
| Takeda Pharmaceuticals U.S.A., INC. | $77.85 | 2023-2024 | Fruzaqla, Alunbrig |
| Merck Sharp & Dohme LLC | $74.06 | 2024-2025 | Keytruda |
| Daiichi Sankyo INC. | $64.22 | 2023-2024 | Enhertu |
| Novartis Pharmaceuticals Corporation | $56.90 | 2023-2025 | |
| G1 Therapeutics, INC. | $54.51 | 2023 | Cosela |
| Mirati Therapeutics, INC. | $52.32 | 2023-2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.69 | 2023-2025 | Gilotrif |
| Janssen Scientific Affairs, LLC | $36.43 | 2024 | Rybrevant, Erleada |
| Janssen Biotech, INC. | $36.05 | 2023-2025 | Rybrevant, Erleada |
| Galvanize Therapeutics, INC | $35.65 | 2025 | Aliya System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $19.86 | 2024 | Ayvakit |
| Tersera Therapeutics LLC | $19.03 | 2025 | Xermelo |
| Deciphera Pharmaceuticals INC. | $18.80 | 2025 | Romvimza, Qinlock |
| Jazz Pharmaceuticals INC. | $18.19 | 2024 | |
| Pharmacosmos Therapeutics INC. | $17.43 | 2024 | Cosela |
| Eisai INC. | $15.61 | 2023 | |
| Aimmune Therapeutics, INC. | $14.99 | 2025 | Zenpep |
| Foundation Medicine, INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Lieber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.